Achaogen Takes $56M In Series C Round

San Francisco-based Achaogen, a biopharmaceuticals firm focused on developing antibiotics, announced today that it has raised $56M in a Series C round. The round was led by Frazier Healthcare Ventures, and included Alta Partners, 5 AM Ventures, ARCH Venture Partners, Domain Associates, Venrock Associates, Versant Ventures and the Wellcome Trust. As part of the funding, Frazier's Robert More joins the company's baord of directors. Achaogen is developing broad-spectrum antibiotics focused on multi-drug resistant (MDR) bacterial infections. More information »